Latest Pharma and Biotech News
Biotechnology
29 April 2025 Shares of US clinical-stage biotech Biohaven rose 9.6% to $21.74 yesterday, after it announced an agreement with Oberland Capital Management for an investment of up to $600 million in the company, with the first tranche of $250 million of gross proceeds to be funded at closing on or before April 30, 2025.
Today's issue
Refine Search
Generics
Swiss generics and biosimilars major Sandoz today presented its net sales update for the first quarter of 2025. 30 April 2025
Pharmaceutical
In a recent study conducted by Navaneethan and colleagues and published in the International Society of Nephrology, the cardiovascular and kidney benefits of German pharma major Bayer’s Kerendia (finerenone) are maintained regardless of acute changes in estimated glomerular filtration rate (eGFR) following treatment initiation in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). 30 April 2025
Pharmaceutical
US-Ireland drugmaker Shorla Oncology has received approval from the US regulator for a new multi-dose vial of Tepylute (thiotepa), a chemotherapy treatment for breast and ovarian cancers. 30 April 2025
Biotechnology
US biotech Regeneron Pharmaceuticals today announced financial results for the first quarter of 2025, showing that total revenues declined 4% to $3.03 billion. 29 April 2025
Pharmaceutical
The European Commission has approved the conversion of the conditional marketing approval (CMA) into a standard marketing authorization (MA) for Filspari (sparsentan). 29 April 2025
Pharmaceutical
Pfizer reported first-quarter 2025 earnings on Tuesday that beat Wall Street expectations, boosted by ongoing cost-cutting efforts and strong demand for its heart disease drug Vyndaqel (tafamidis). 29 April 2025
Pharmaceutical
Italian pharma major Recordati has set new three-year financial targets for the period 2025-2027, aiming for fiscal year (FY) 2027 revenues of 3.0–3.2 billion euros ($4.1-$4.4 billion) and earnings before interest, tax, depreciation and amortization (EBITDA) of 1.14–1.225 billion euros, driven by a balanced strategy of organic growth, rare disease leadership, and targeted M&A. 29 April 2025
Biotechnology
Shares of US clinical-stage biotech Biohaven rose 9.6% to $21.74 yesterday, after it announced an agreement with Oberland Capital Management for an investment of up to $600 million in the company, with the first tranche of $250 million of gross proceeds to be funded at closing on or before April 30, 2025. 29 April 2025
Pharmaceutical
The Novo Nordisk Foundation has opened its largest research funding initiative, the Challenge Programme, to applicants based outside Denmark for the first time, allowing researchers from the European Schengen area, Ireland and the UK to lead new collaborations. 29 April 2025
Biotechnology
Early-stage biotech Nova Anchora has secured a new investment to move its lead therapy for epidermolysis bullosa (EB) closer to clinical trials. 29 April 2025
Pharmaceutical
AstraZeneca posted a 10% rise in first-quarter revenue to $13.6 billion, supported by strong sales of cancer drugs and biopharmaceuticals. Core earnings per share climbed 21% to $2.49, while reported EPS advanced 34% to $1.88. Pre-tax profits increased 21% year-on-year to $3.4 billion. 29 April 2025
Pharmaceutical
Swiss pharma giant Novartis this morning posted first-quarter 2025 financials, showing that net sales were $13.2 billion (+12%, +15% constant currency), with volume contributing 15 percentage points to growth, compared to the $13.12 billion estimated by analysts in an LSEG poll. Novartis shares were up around 1.2% in early trading. 29 April 2025
Biotechnology
USA-based Medicus Pharma has agreed to acquire UK firm Antev for around $75 milln in a share exchange deal. 28 April 2025
Biotechnology
Regeneron Pharmaceuticals today announced that the European Commission (EC) has granted conditional marketing approval of Lynozyfic (linvoseltamab) to treat adults with relapsed and refractory (R/R) multiple myeloma. 28 April 2025
Pharmaceutical
The USA faces a serious risk of measles becoming endemic again, according to a new study modeling the impact of declining childhood vaccination rates, published in JAMA. 28 April 2025
Biotechnology
Merck & Co has announced results from the Phase III KEYNOTE-689 trial of Keytruda (pembrolizumab) as a perioperative treatment regimen for patients with stage III or IVA, resected, locally advanced head and neck squamous cell carcinoma (LA-HNSCC). 28 April 2025
Biotechnology
Comac Medical, a full-service contract research organization (CRO) based in Bulgaria, has announced major leadership changes alongside an international expansion drive, under the ownership of investment firm EdgeCap Partners. 28 April 2025
Biotechnology
Shares of French speciality vaccines developer Valneva were down 8.4% at 2.89 euros by early afternoon, after it announced a negative decision by France’s national public health agency. 28 April 2025
Pharmaceutical
A new category of diabetes, known as type 5 diabetes, has been officially recognized by the International Diabetes Federation during its World Diabetes Congress. The condition, previously referred to as malnutrition-related diabetes, is distinct from both type 1 and type 2 diabetes. 28 April 2025
Pharmaceutical
After reported discussions since February, German pharma and sciences company Merck KGaA has confirmed its intension to acquire the US drug developer SpringWorks Therapeutics. 28 April 2025
All news
Pharmaceutical
Australia’s Recce Pharmaceuticals has announced positive data from a Phase II trial evaluating RECCE 327 Topical Gel (R327G) for the treatment of acute bacterial skin and skin structure infections (ABSSSI), with the news pushing the firm’s shares up around 9%. 19 February 2025
Biotechnology
Boston, USA-based biotech Solid Biosciences saw its shares rocket 36% to $5.48 yesterday, after the precision genetic medicines for neuromuscular and cardiac diseases company announced positive initial data from the Phase I/II INSPIRE DUCHENNE trial evaluating SGT-003. 19 February 2025
Pharmaceutical
US biotech Gilead Sciences has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for lenacapavir—the company’s twice-yearly injectable HIV-1 capsid inhibitor—for the prevention of HIV as pre-exposure prophylaxis (PrEP). 19 February 2025
Biotechnology
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) to Dutch clinical-stage drug developer Merus for its petosemtamab. 19 February 2025
Pharmaceutical
Danish pharma major Novo Nordisk has sued KBP Biosciences and its founder and executive chairman, Huang Zhenhua, for $830 million in an application to the Singapore International Commercial Court. 19 February 2025
Biotechnology
US clinical-stage biotech Septerna yesterday announced its decision to discontinue the Phase I single- and multiple-ascending dose (SAD/MAD) clinical trial of SEP-786 in healthy volunteers. SEP-786 is an oral small molecule agonist of the parathyroid hormone 1 receptor (PTH1R) being developed for the treatment of hypoparathyroidism. 19 February 2025
Biotechnology
Barcelona, Spain-based biotech Ona Therapeutics today announced key leadership appointments to support its rapid growth and pipeline advancement. 19 February 2025
Pharmaceutical
Nura Bio, a US biopharma developing neuroprotective, small molecule therapies for the treatment of debilitating neurological diseases, has announced the appointments of Lahar Mehta as chief medical officer and Scott Greenberg as chief business officer. 18 February 2025
Pharmaceutical
Israel-based clinical-stage company Purple Biotech today announced it is advancing into a Phase II study with NT219 in patients with recurrent/metastatic squamous cell carcinoma. of the head and neck (R/M SCCHN), with the news pushing its shares up as much as 10% to 6.50 shekels. 18 February 2025
Biotechnology
Epitopea, an Anglo-Canadian company developing accessible, off-the-shelf RNA-based immunotherapies for cancer, has announced a license and research collaboration deal with US pharma giant Merck & Co to identify Cryptigen tumor-specific antigens (TSAs) in an undisclosed solid tumor. 18 February 2025
Pharmaceutical
Germany’s Merck KGaA has appointed three new members to its executive board, which it says is a natural evolution in the company’s leadership as it continues to implement its growth strategy. 18 February 2025
Biotechnology
Swiss dermatology company Galderma has announced two European approvals for Nemluvio (nemolizumab) to treat both atopic dermatitis and prurigo nodularis. 18 February 2025
Pharmaceutical
US pharma giant Merck & Co today announced that the European Commission (EC) has conditionally approved two indications for Welireg (belzutifan), its oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor. 18 February 2025
Pharmaceutical
Stoke Therapeutics’ stock climbed 8% early Tuesday, after the company and Biogen today announced a collaboration to develop and commercialize a treatment for Dravet Syndrome, a severe form of epilepsy that starts in childhood. 18 February 2025
Biotechnology
California-based Arcus Biosciences, a biopharma developing differentiated molecules and combination therapies for people with cancer, has presented new data for casdatifan, a HIF-2a inhibitor with best-in-class potential, in metastatic kidney cancer. 18 February 2025
Pharmaceutical
According to new research announced today, the fragile X syndrome (FXS) market across the USA and Germany is projected to experience explosive growth, quadrupling from $28.7 million in 2025 to $111.9 million by 2030, a compound annual growth rate (CAGR) of 31.3% (2025-2030), driven by the anticipated launch of two high-priced targeted therapies for FXS in 2027. 18 February 2025
Biotechnology
The US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults with bullous pemphigoid (BP). 18 February 2025
Biotechnology
French clinical-stage biotech AlgoTherapeutics (AlgoTx) today announced the completion of its 276 patient Phase II trial, known as ACT, with ATX01 in chemotherapy-induced peripheral neuropathy (CIPN). 18 February 2025
Biotechnology
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Altuvoct (efanesoctocog alfa) to be used to treat and prevent bleeding in patients aged two years and above with severe or moderate hemophilia A. 18 February 2025
Pharmaceutical
AstraZeneca, Moderna and Novo Nordisk have breached the Association of the British Pharmaceutical Industry (ABPI) Code of Practice for the Pharmaceutical Industry. 17 February 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze